Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 8/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | CHKB | Q9Y259 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6723840 | 0.95 | CHKA (0.38) | CHKAPTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL6723989 | 0.95 | CHKA (0.38) | CHKAPTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL6724024 | 0.91 | PTGER1 (0.37) | CHKAPTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL21673236 | 0.91 | ALDH1A1 (0.44) | CHKAPTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL6724306 | 0.91 | PTGER1 (0.41) | PTGER1PTGER4PTGER3PTGER2MAOA | |
| SCHEMBL6724005 | 0.89 | CHKA (0.39) | CHKAMAOAPDE5ATACR1 | |
| SCHEMBL22807881 | 0.89 | CHKA (0.40) | CHKACHKBPDE5ATACR1 | |
| SCHEMBL27498154 | 0.89 | PTPN1 (0.41) | CHKAPTPN1CES1EGFRSRC | |
| SCHEMBL6723582 | 0.87 | CHKA (0.41) | CHKAPTPN1CES1EGFRSRC | |
| SCHEMBL6723411 | 0.87 | PTPN1 (0.42) | CHKAPTPN1CES1EGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178216-B2 | Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178216-B2 | Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20090072718-A1 | Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2009-03-19 | — | — | US | disclosed |
| US-20090072718-A1 | Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090072718-A1 | Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative | CRY1, GRK1, CRY2 | CHKA 4185/4885PTGER1 218/4885PTGER4 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.